Skip to main content
NVDA-2.56%AAPL+2.09%GOOGL-0.15%MSFT+0.01%AMZN+0.07%TSM-1.00%SPCX+1.78%AVGO+0.04%META+0.01%TSLA-0.58%SKHY-4.03%MU-4.48%BRK-B-0.15%LLY+0.70%JPM-0.44%AMD-2.55%WMT+0.12%V-0.15%XOM+0.11%ASMLa-1.82%JNJ-0.04%INTC-4.41%MA-0.47%0700.HK-1.94%ORCL-2.24%1398.HK+0.79%BAC-0.50%ABBV+0.55%CSCO-0.53%CVX-0.46%COST+0.03%LRCX-3.93%KO+0.97%CAT-1.09%AMAT-2.32%0005.HK-0.78%AP2d-1.57%UNH-0.67%DELL-2.77%HSBA.L-1.17%MS-0.21%PG-0.22%GE-0.11%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.11%HD-0.96%GS-0.39%0939.HK+1.66%NZDJPY-2.69%AUDJPY-1.94%CHFJPY-1.66%USDJPY-1.50%NZDCAD-1.38%GBPJPY-1.38%EURJPY-1.37%EURNZD+1.37%CADJPY-1.32%GBPNZD+1.32%NZDUSD-1.22%NZDCHF-1.06%USDNOK+0.91%EURNOK+0.88%CHFNOK+0.80%AUDNZD+0.78%USDZAR+0.76%EURZAR+0.73%USDSEK+0.70%NOKJPY-0.68%EURSEK+0.66%GBPZAR+0.66%AUDCAD-0.65%AUDDKK-0.62%CHFSEK+0.59%EURAUD+0.58%GBPAUD+0.54%AUDSGD-0.49%USDMXN+0.46%AUDUSD-0.45%USDTHB+0.45%GBPTRY+0.41%NZDSGD-0.33%GBPHKD+0.32%CADCHF+0.32%AUDCHF-0.29%GBPMXN-0.28%EURCHF+0.28%AUDNOK+0.26%GBPCHF+0.26%USDPLN+0.25%EURPLN+0.21%USDCAD-0.17%USDCHF+0.17%USDILS+0.16%USDSGD+0.16%EURUSD+0.13%EURSGD+0.12%GBPUSD+0.11%USDTRY+0.11%EURCZK-0.08%GBPCAD-0.08%SGDJPY+0.08%USDCNH+0.06%NZDMXN-0.05%EURHKD-0.05%EURCAD-0.05%CHFSGD+0.04%EURCNH+0.04%USDCOP-0.04%EURGBP+0.04%USDDKK+0.04%GBPSGD+0.03%PLNJPY-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.93%HG1-4.65%GAGUSD-4.13%XAGUSD-4.13%UKOIL+3.72%USOIL+3.33%SUGAR+1.74%COCOA+1.05%GAUUSD-0.89%XAUUSD-0.89%S1+0.76%COTTON+0.71%BTCUSD-1.46%ETHUSD-1.30%USDTUSD-0.02%XRPUSD-2.93%SOLUSD-1.81%TRXUSDT-0.03%ZECUSDT-6.32%DOGEUSD-3.23%XMRUSDT-2.05%LINKUSD-1.53%XLMUSD-2.24%BCHUSDT-11.18%LTCUSD-2.07%UNIUSD-3.99%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.84%TAOUSDT-5.84%AAVEUSD-3.26%DOTUSDT-3.07%ICPUSDT-1.15%ONDOUSDT-3.26%WLDUSDT-3.39%ATOMUSDT-4.43%ARBUSDT+0.43%JUPUSDT-3.82%INJUSDT-5.31%STXUSDT-3.80%FETUSDT-4.15%TIAUSDT-1.39%PYTHUSDT-0.37%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-3.34%WIFUSDT-5.38%OPUSDT-4.00%IOTAUSDT-4.12%POLUSDT-5.95%AXSUSDT-2.90%FARTCOINUSDT-3.37%EOSUSDT-0.93%DYDXUSDT-1.19%ORDIUSDT-1.43%GALAUSDT-5.34%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.56%AAPL+2.09%GOOGL-0.15%MSFT+0.01%AMZN+0.07%TSM-1.00%SPCX+1.78%AVGO+0.04%META+0.01%TSLA-0.58%SKHY-4.03%MU-4.48%BRK-B-0.15%LLY+0.70%JPM-0.44%AMD-2.55%WMT+0.12%V-0.15%XOM+0.11%ASMLa-1.82%JNJ-0.04%INTC-4.41%MA-0.47%0700.HK-1.94%ORCL-2.24%1398.HK+0.79%BAC-0.50%ABBV+0.55%CSCO-0.53%CVX-0.46%COST+0.03%LRCX-3.93%KO+0.97%CAT-1.09%AMAT-2.32%0005.HK-0.78%AP2d-1.57%UNH-0.67%DELL-2.77%HSBA.L-1.17%MS-0.21%PG-0.22%GE-0.11%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.11%HD-0.96%GS-0.39%0939.HK+1.66%NZDJPY-2.69%AUDJPY-1.94%CHFJPY-1.66%USDJPY-1.50%NZDCAD-1.38%GBPJPY-1.38%EURJPY-1.37%EURNZD+1.37%CADJPY-1.32%GBPNZD+1.32%NZDUSD-1.22%NZDCHF-1.06%USDNOK+0.91%EURNOK+0.88%CHFNOK+0.80%AUDNZD+0.78%USDZAR+0.76%EURZAR+0.73%USDSEK+0.70%NOKJPY-0.68%EURSEK+0.66%GBPZAR+0.66%AUDCAD-0.65%AUDDKK-0.62%CHFSEK+0.59%EURAUD+0.58%GBPAUD+0.54%AUDSGD-0.49%USDMXN+0.46%AUDUSD-0.45%USDTHB+0.45%GBPTRY+0.41%NZDSGD-0.33%GBPHKD+0.32%CADCHF+0.32%AUDCHF-0.29%GBPMXN-0.28%EURCHF+0.28%AUDNOK+0.26%GBPCHF+0.26%USDPLN+0.25%EURPLN+0.21%USDCAD-0.17%USDCHF+0.17%USDILS+0.16%USDSGD+0.16%EURUSD+0.13%EURSGD+0.12%GBPUSD+0.11%USDTRY+0.11%EURCZK-0.08%GBPCAD-0.08%SGDJPY+0.08%USDCNH+0.06%NZDMXN-0.05%EURHKD-0.05%EURCAD-0.05%CHFSGD+0.04%EURCNH+0.04%USDCOP-0.04%EURGBP+0.04%USDDKK+0.04%GBPSGD+0.03%PLNJPY-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.93%HG1-4.65%GAGUSD-4.13%XAGUSD-4.13%UKOIL+3.72%USOIL+3.33%SUGAR+1.74%COCOA+1.05%GAUUSD-0.89%XAUUSD-0.89%S1+0.76%COTTON+0.71%BTCUSD-1.46%ETHUSD-1.30%USDTUSD-0.02%XRPUSD-2.93%SOLUSD-1.81%TRXUSDT-0.03%ZECUSDT-6.32%DOGEUSD-3.23%XMRUSDT-2.05%LINKUSD-1.53%XLMUSD-2.24%BCHUSDT-11.18%LTCUSD-2.07%UNIUSD-3.99%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.84%TAOUSDT-5.84%AAVEUSD-3.26%DOTUSDT-3.07%ICPUSDT-1.15%ONDOUSDT-3.26%WLDUSDT-3.39%ATOMUSDT-4.43%ARBUSDT+0.43%JUPUSDT-3.82%INJUSDT-5.31%STXUSDT-3.80%FETUSDT-4.15%TIAUSDT-1.39%PYTHUSDT-0.37%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-3.34%WIFUSDT-5.38%OPUSDT-4.00%IOTAUSDT-4.12%POLUSDT-5.95%AXSUSDT-2.90%FARTCOINUSDT-3.37%EOSUSDT-0.93%DYDXUSDT-1.19%ORDIUSDT-1.43%GALAUSDT-5.34%NOTUSDT-2.97%RONINUSDT-2.64%
IN

Innoviva, Inc. (INVA)

NASDAQ • Healthcare

$21.13
-$0.21 (-1.0%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$21.16
Previous Close$21.13
Day Range$20.77 - $21.41
Avg. Volume (3M)616.7K
Market Cap$1.5B
P/E Ratio4.3
52 Week Range
$16.52$25.15
Next EarningsIn 55 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$119.5M100%
Gross Profitminus cost of goods$90.6M76%
Operating Incomeminus R&D and overhead$50.8M43%

In plain terms: out of every $100 in revenue, Innoviva, Inc. currently loses $70.

Fundamentals & Financials

Revenue (TTM)
$443.4M
Net Income (TTM)
$357.2M
EPS (TTM)
$4.87
ROA (TTM)
20.98%
Current Ratio
16.01
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+470.6%Q1 2026$1.94
+2.3%Q2 2026$0.44
+161.5%Q3 2026$1.14
Next

Nov 4

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Innoviva, Inc.

Innoviva, Inc. is a NASDAQ-listed biotechnology company that earns royalty-based revenue from partnered respiratory medicines. The company recorded $425.1 million of revenue in FY2025. Formerly known as Theravance, Inc., it sits in the healthcare sector and centers its economics on products commercialized through a collaboration with Glaxo Group Limited.

Name
Innoviva, Inc.
CEO
Pavel Raifeld
Website
www.inva.com
Industry
Healthcare
Year Founded
1996
Employees
159

Today's Snapshot

AI-generated

INVA opened slightly lower at 21.05, while its sector was flat. Innoviva outlined growth plans beyond COPD royalties at a Cantor Fitzgerald investor conference.

Trading Volume

Below 10d avg (616.3K)

66.4K

vs S&P 500 Today

Underperforming Market

-0.86%

Updated: September 10, 2026 at 15:12 UTC

Technical Indicators

0 Buy3 Neutral5 Sell
INVA leans toward a bearish posture despite muted indicators, with recent momentum barely negative and the market price generally sitting under several short- and longer-term moving averages, including the 200-day, which suggests limited upside conviction. ADX shows a very weak trend, implying low directional force, and while on-balance volume points to some accumulation, it hasn’t translated into price strength. Volatility and oscillators are neutral, so the bias is chiefly driven by the moving-average alignment and weak momentum. Technical takeaway: Sell — lackluster momentum and price below key averages favor a bearish bias.
All signals
  • EMA (5 indicators)$21.16 - $21.65
    Sell
  • RSI (14)47.47
    Neutral
  • Stochastic %K (14, 3, 3)55.50
    Neutral
  • MACD Level (12, 26)-0.03
    Neutral

Peers & Related Assets

DNTHDianthus Therapeutics, Inc.
$107.04-1.9%
ELVNEnliven Therapeutics, Inc.
$57.45-3.2%
RLAYRelay Therapeutics, Inc.
$18.66-2.4%
SNDXSyndax Pharmaceuticals, Inc.
$19.84-0.5%
INBXInhibrx Biosciences Inc.
$112.86-1.3%
MDXGMiMedx Group, Inc.
$4.68+0.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.